Dashboard

E-Commentary


Sponsored

Skin Vibes Clinic

Dermatologist in Santacruz | Skin Vibes Clinic
Directory:
Expertise:

Discover comprehensive solutions for all skin concerns at Skin Vibes Clinic, led by renowned doctors Dr. Anju Methil and Dr. Viral Desai, associated with Clinicspots as medical advisors. Our globally prominent methods ensure effective results, emphasizing beauty as an investment. Start your skin-vestment wisely with us today.


view this profile

Over the years, our dental center gained a local reputation for excellent and gentle dental care, using the latest state-of-the-art equipment and cutting-edge technology, upholding the strictest sterilization techniques. Many people may feel anxious about visiting the top-rated dentist, so we aim to make your visit with us as pain and anxiety-free as possible. Our mission is to educate our patients about all of their oral health care options and help guide them to choose a treatment plan that is most suitable and appropriate for their needs.

Google Maps: https://maps.app.goo.gl/oksyfTuQodLzAix68 

https://plus.codes/87G7VWWW+8X 
Nearby Locations & Municipalities:
Maywood | Teaneck | Lodi | Little Ferry | Ridgefield Park | Hasbrouck Heights | River Edge | Saddle Brook | Palisades Park | New Milford | Garfield | Englewood | Bergenfield | Ridgefield | Elmwood Park

Nearby Zip Codes
07601 | 07602 | 07603 | 07604 | 07666 | 07644 | 07643 | 07660 | 07657 | 07661 | 07663 | 07663 | 07650 | 07646 | 07631 | 07632 | 07621 | 07657

My New Jersey Dentist
385 Prospect Ave, Suite 304,
Hackensack, NJ 07601
(201) 425–9580
Web Address: https://mynjdentist.com/ 

Working Hours:
Monday-Friday: 10:00am — 6:00pm
Saturday: 9:00am — 3:00pm
Sunday: by appointment only

Payment: cash, check, credit cards.

view in full page

My New Jersey Dentist

Dr. Victoria Kushensky, DDS

The Best Dentist in Hackensack, Bergen County.
If you are looking for a highly trained, experienced, and skilled dentist in Hackensack, you have come to the right place. At our practice, you will receive the highest quality, individualized, compassionate, and patient-centric dental care using evidence-based and time-tested treatments. Whether you need cosmetic dentistry, orthodontics, periodontics, or pediatric dentistry, board-certified dentists at My New Jersey Dentist will ensure you are safe and comfortable while receiving the highest quality conservative dental care to preserve your beautiful smile and achieve optimal oral health and overall well-being. Not only can you trust us with your teeth, but your children’s teeth as well.

Over the years, our dental center gained a local reputation for excellent and gentle dental care, using the latest state-of-the-art equipment and cutting-edge technology, upholding the strictest sterilization techniques. Many people may feel anxious about visiting top dental specialist, so we aim to make your visit with us as pain and anxiety-free as possible. Our mission is to educate our patients about all of their oral health care options and help guide them to choose a treatment plan that is most suitable and appropriate for their needs. Visit the dental implant dentist near me.

Our services:

Google Maps: https://maps.app.goo.gl/oksyfTuQodLzAix68 

https://plus.codes/87G7VWWW+8X 
Nearby Locations & Municipalities:
Maywood | Teaneck | Lodi | Little Ferry | Ridgefield Park | Hasbrouck Heights | River Edge | Saddle Brook | Palisades Park | New Milford | Garfield | Englewood | Bergenfield | Ridgefield | Elmwood Park

Nearby Zip Codes
07601 | 07602 | 07603 | 07604 | 07666 | 07644 | 07643 | 07660 | 07657 | 07661 | 07663 | 07663 | 07650 | 07646 | 07631 | 07632 | 07621 | 07657

My New Jersey Dentist
385 Prospect Ave, Suite 304,
Hackensack, NJ 07601
(201) 425–9580
Web Address: https://mynjdentist.com/ 

Working Hours:
Monday-Friday: 10:00am — 6:00pm
Saturday: 9:00am — 3:00pm
Sunday: by appointment only

Payment: cash, check, credit cards.

Our social links:

https://www.facebook.com/404576020134173 

https://twitter.com/mynjdentist 

https://www.linkedin.com/company/mynjdentist/about/ 

https://www.instagram.com/mynjdentist/ 

https://www.youtube.com/@MyNewJerseyDentist 

https://www.yelp.com/biz/my-new-jersey-dentist-hackensack 

https://www.tumblr.com/mynjdentists 

https://www.pinterest.com/mynjdentists/ 

https://www.tiktok.com/@mynjdentists 

Find us at: https://doctor.webmd.com/doctor/victoria-kushensky-bd5a2673-7395-4c29-88f7-015263eaaccf-overview 

View other locations My New Jersey Dentist has been mentioned:

https://www.tellows.com/num/2014259580

http://www.dexknows.com/hackensack-nj/bp/my-new-jersey-dentist-558963395 

https://www.cylex.us.com/company/my-new-jersey-dentist-27934118.html 

https://maps.apple.com/place?auid=13125569443897478917

http://www.superpages.com/hackensack-nj/bpp/my-new-jersey-dentist-558963395 


view this profile

We’re thrilled to welcome Dr. Victoria Kushensky, D.D.S., to My NJ Dentist! Dr. Kushensky is a skilled general dentist in Bergen County, NJ with a passion for staying at the forefront of her field. Combining compassionate care with extensive knowledge, she offers general dentistry services and advanced root canal treatments to patients in Hackensack.

Educational Background
Dr. Kushensky is a dedicated and experienced dentist committed to providing exceptional dental care to patients in Hackensack, NJ. She earned her Doctor of Dental Surgery (DDS) from the prestigious New York University College of Dentistry.

Field Experience
Throughout her career, Dr. Kushensky has honed her skills in a variety of dental procedures, ensuring she can effectively address your unique needs.

She has extensive experience in:

  • Root Canal Therapy: Dr. Kushensky can save your tooth from extraction with a comfortable and efficient root canal procedure.
  • General Dentistry: From routine cleanings and fillings to gum disease treatment, Dr. Kushensky provides comprehensive general dentistry services to maintain your oral health.
  • Cosmetic Dentistry: Looking for a brighter, more confident smile? Dr. Kushensky offers cosmetic dentistry services like dental crowns and veneers to create a beautiful smile you’ll love. 

Dr. Kushensky prioritizes patient comfort and understanding. She takes the time to explain procedures thoroughly and answer any questions you may have.

Training
Dr. Victoria Kushensky is known for her dedication to continuous learning and professional growth in the field of dentistry. This commitment is demonstrated through her active participation in various educational programs offered by Implant Seminars, Inc., an organization recognized by the Academy of General Dentistry as an Approved PACE Program Provider.

Dr. Kushensky enriched her knowledge and skills by attending two key courses. The first, “Autologous Blood Concentrates”, provided insights into the advantages and limitations of different commercially available systems, taught a cost-effective, scientifically validated method to boost patients’ hard and soft tissue healing using a straightforward centrifuge, and offered hands-on experience in phlebotomy techniques.

The second comprehensive program, “Implantology Unlimited”, covered:

  • patient evaluation
  • dental implant treatment planning
  • review of graft materials and membranes
  • detailed socket preservation and implant placement techniques

Both courses were facilitated by respected professionals in the field, including Dr. Arun K. Garg, Charles Biami, and Elijah Desmond, spanning various subjects such as Basic Science, Oral & Maxillofacial Surgery, Periodontics, and Implants.

Google Maps: https://maps.app.goo.gl/oksyfTuQodLzAix68 

https://plus.codes/87G7VWWW+8X 

Nearby Locations & Municipalities:
Maywood | Teaneck | Lodi | Little Ferry | Ridgefield Park | Hasbrouck Heights | River Edge | Saddle Brook | Palisades Park | New Milford | Garfield | Englewood | Bergenfield | Ridgefield | Elmwood Park

Nearby Zip Codes
07601 | 07602 | 07603 | 07604 | 07666 | 07644 | 07643 | 07660 | 07657 | 07661 | 07663 | 07663 | 07650 | 07646 | 07631 | 07632 | 07621 | 07657

My New Jersey Dentist
385 Prospect Ave, Suite 304,
Hackensack, NJ 07601
(201) 425–9580
Web Address: https://mynjdentist.com/ 

Working Hours:
Monday-Friday: 10:00 am — 6:00 pm
Saturday: 9:00 am — 3:00 pm
Sunday: by appointment only

Payment: cash, check, credit cards.

Find us at: https://doctor.webmd.com/doctor/victoria-kushensky-bd5a2673-7395-4c29-88f7-015263eaaccf-overview


view this profile

Eye Physicians

Dr. William Hogue, OD

World-class optometry and ophthalmology care and cutting-edge technology distinguish Eye Physicians. Our New York City ophthalmologists and optometrists trained and served as educators at some of the world’s most esteemed and highly regarded academic institutions.

NYC Eye Physicians are proud to be on USA Newsweek’s list of 350 best ophthalmologists and optometrists. Using the latest advancements and techniques in optometric practices, our doctors offer a full range of Optometry & Ophthalmology services, from eye exam and treatment for dry eyes, burning eyes, and eye stye to an accurate assessment of refractive errors, like nearsightedness/farsightedness/astigmatism, and eyeglasses or contact lenses. At Manhattan Eye Physicians, you’ll find the individualized, compassionate and patient-centric Optometry & Ophthalmology care you need in the safe, reassuring hands of eye experts.

To provide more comprehensive eye care, our ophthalmologists Downtown use the newest diagnostic equipment available in the USA, such as Optical Coherence Tomography (OCT), Digital Slit Lamps, Automated Phoropters, Zeiss Visual Field Analyzers, VT1 Vision Screeners and Retina Cameras. These technologies offer earlier detection of various eye-related conditions and improved patient outcomes.

Conveniently located in the NYC Downtown, the Eye Physicians centers boast state-of-the-art, certified, and approved optometry and ophthalmology facilities. Visit our office near you and meet our eye physicians NYC Richard F. Spaide, MD, Michael J. Cooney, MD, MBA, and William Hogue, OD, to experience skill, knowledge, and compassion. For excellent patient care, make your appointment today at (212) 292-4814. Visit the emergency eye doctor near me

Eye Physicians
110 Lafayette St, Suite 503
New York, NY 10013
Office Tel: (212) 292-4814
Fax: (212) 628-0698
Web Address: https://www.myeyephysicians.com/ 

Our locations on the map: https://maps.app.goo.gl/pkDgr4UdoZSScuaR7 

https://plus.codes/87G7PX9X+8M New York, USA

Nearby Locations:

Lower Manhattan | Little Italy | Chinatown | Civic Center | Tribeca | SoHo
10013 | 10012 | 10007 | 10002

Working Hours:
Monday: 8 am–5 pm
Tuesday: 8 am–5 pm
Wednesday: 8 am–7 pm
Thursday: 8 am–5 pm
Friday: 8 am–5 pm
Saturday: 8 am–5 pm
Sunday: Closed

Payment: cash, check, credit cards.

Our social links:

https://www.facebook.com/eyephysiciansny/ 

https://twitter.com/myeyephysicians 

https://www.linkedin.com/company/eye-physicians/ 

https://www.instagram.com/eyephysiciansny/ 

https://www.youtube.com/@EyePhysiciansNY 

https://www.yelp.com/biz/eye-physicians-new-york 

https://www.tumblr.com/myeyephysicians 

https://www.pinterest.com/myeyephysicians/ 

https://www.tiktok.com/@myeyephysicians 

 

Read more: https://doctor.webmd.com/doctor/william-hogue-44709d70-6f80-4e3b-8362-636ac839a880-overview 

 

View other locations Eye Physicians has been mentioned

https://www.merchantcircle.com/eye-physicians-new-york-ny 

https://www.mylocalservices.com/Eye+Physicians-New+York-New+York-24612168.html 

https://www.cylex.us.com/company/eye-physicians-37629686.html

https://find-open.com/new-york/eye-physicians-14457942 

https://www.tupalo.co/new-york-city/eye-physicians


view this profile

NYC Eye Physicians are proud to be on USA Newsweek’s list of 350 best ophthalmologists and optometrists. Using the latest advancements and techniques in optometric practices, our doctors offer a full range of Optometry & Ophthalmology services, from eye exams and treatment for dry eyes, burning eyes, and eye stye to an accurate assessment of refractive errors, like nearsightedness/farsightedness/astigmatism, and eyeglasses or contact lenses. At Manhattan Eye Physicians, you’ll find the individualized, compassionate and patient-centric Optometry & Ophthalmology care you need in the safe, reassuring hands of eye experts.

To provide more comprehensive eye care, our optometrists use the newest diagnostic equipment available in the USA, such as Optical Coherence Tomography (OCT), Digital Slit Lamps, Automated Phoropters, Zeiss Visual Field Analyzers, VT1 Vision Screeners and Retina Cameras. These technologies offer earlier detection of various eye-related conditions and improved patient outcomes.

Eye Physicians
110 Lafayette St, Suite 503
New York, NY 10013
Office Tel: (212) 292-4814
Fax: (212) 628-0698
Web Address: https://www.myeyephysicians.com/ 

Our locations on the map: https://maps.app.goo.gl/pkDgr4UdoZSScuaR7 

https://plus.codes/87G7PX9X+8M New York, USA

Nearby Locations:

Lower Manhattan | Little Italy | Chinatown | Civic Center | Tribeca | SoHo
10013 | 10012 | 10007 | 10002

Working Hours:
Monday: 8 am–5 pm
Tuesday: 8 am–5 pm
Wednesday: 8 am–7 pm
Thursday: 8 am–5 pm
Friday: 8 am–5 pm
Saturday: 8 am–5 pm
Sunday: Closed

Payment: cash, check, credit cards.

 

 

view in full page

After getting glasses at a young age, Dr. Hogue noticed the startling improvement that vision correction can make. This early experience propelled him to pursue a career where he could make an immediate, positive impact in people’s lives.

Dr. Hogue graduated summa cum laude from the University of Tennessee with a degree in chemistry. He then earned his Doctorate of Optometry (OD) and Master of Science (MS) from New England College of Optometry. Following graduation, he completed a residency in Ocular Disease at the State University of New York’s College of Optometry.

Eye Physicians
110 Lafayette St, Suite 503
New York, NY 10013
Office Tel: (212) 292-4814
Fax:  (212) 628-0698
Web Address: https://www.myeyephysicians.com/ 

Our locations on the map: https://maps.app.goo.gl/pkDgr4UdoZSScuaR7 

https://plus.codes/87G7PX9X+8M New York, USA

Nearby Locations:

Lower Manhattan | Little Italy | Chinatown | Civic Center | Tribeca | SoHo
10013 | 10012 | 10007 | 10002

Working Hours:
Monday: 8 am–5 pm
Tuesday: 8 am–5 pm
Wednesday: 8 am–7 pm
Thursday: 8 am–5 pm
Friday: 8 am–5 pm
Saturday: 8 am–5 pm
Sunday: Closed

Payment: cash, check, credit cards.

Find us at: https://care.everydayhealth.com/providers/6489318/william-donald-hogue-od-ms/ 


view this profile
joined 2 years, 1 month ago

Virginia Hearing Consultants

Virginia Hearing Consultants
Directory:
Expertise:

If you're searching for a trusted medical clinic in Virginia Beach that specializes in audiology, look no further than Virginia Hearing Consultants. Our facility is staffed with experienced audiologists dedicated to improving the hearing health of our community. We understand the impact that hearing issues can have on your quality of life and are equipped to offer comprehensive services tailored to meet individual needs. Our audiology practice is equipped with state-of-the-art diagnostic tools to ensure accurate assessments and treatments for a variety of hearing conditions. As a prominent medical clinic in the area, we pride ourselves on our patient-centered approach, ensuring that everyone who walks through our doors receives attentive care and personalized treatment plans. Whether you need routine hearing evaluations or more complex auditory treatments, Virginia Hearing Consultants is ready to assist you with top-notch audiological care right here in Virginia Beach.

Phone: 757-461-4327


view this profile
Directory:
Tags:

Henry Wendt, 1933 - 2024
Obituary

Henry Wendt, born on July 19, 1933, in Neptune City, NJ, passed away on April 11, 2024, leaving behind a legacy that will endure for generations. Raised in Sands Point and Tuxedo Park NY, Henry embarked on a journey after graduating from Princeton University in 1955, starting his career as a salesperson for Smith, Kline & French, an American pharmaceutical company. His dedication and strategic acumen propelled him through various roles within the corporation, spanning locations such as Hawaii, Montreal, Tokyo, and Philadelphia, ultimately culminating in his appointment as President and CEO in 1976.
 
As CEO, Henry implemented a transformative 3-point strategy, reshaping the company's trajectory through strategic divestments and a focus on core products. This foresight laid the groundwork for the historic merger in 1989 with the UK-based Beecham Company, resulting in the formation of SmithKline Beecham (SKB). This was the largest cross-border merger of its time, and heralded the birth of a truly transnational corporation that would redefine global competition in the pharmaceutical industry. Under Henry's leadership, SKB emerged as the world’s second largest pharmaceutical company, both in prescription and over-the-counter drugs, solidifying its position as a global powerhouse.
 
Henry was more than just a businessperson; he was a visionary who recognised the significance of the evolving nature of transnational corporations. In his book, Global Embrace, published in 1993, he described a transition from the era of multinationals to the rise of transnational enterprises, painting a picture of a world where corporate operations transcended national borders in the pursuit of progress and prosperity. Henry's conceptualisation of transnational entities diverged from traditional multinationals primarily in their ownership structure. Unlike their predecessors, transnational corporations boasted a shareholder base that spanned the globe, marking a departure from the conventional reliance on temporary global marketing strategies like foreign branches, offshore acquisitions, joint ventures, or licensing agreements. This distinction emphasised a shift towards a more interconnected and globally oriented business paradigm. Henry's work not only explored market dynamics and competitive strategies but also explored the broader societal implications of this emerging corporate model, advocating for policies that fostered international cooperation and celebrated cultural diversity.

Henry Wendt's influence reached far beyond the boardroom, embodying integrity, moral fortitude, and an unwavering commitment to his country. His life epitomised timeless values of fairness, honesty, and optimism, evident in his many achievements and philanthropic endeavours. His diverse interests mirrored his commitment to improving society, seen through initiatives such as establishing academic chairs, sponsoring educational programmes, and funding research laboratories nationwide. A polymath, Henry found fulfilment in exploration, whether navigating the seas or delving into the realms of knowledge. Through ventures like the Quivira Estate Vineyards and Winery and his contributions to academia and research, his enduring impact continues to inspire future generations. In his passing, Henry Wendt leaves behind a rich legacy of leadership, generosity, and foresight that will echo through the years, serving as a powerful testament to the impact an individual can have on shaping a better world.

  
view in full page
  • MedTechs traditionally prioritise M&A over in-house R&D yielding size without always improving quality
  • Amidst healthcare's rapid evolution, companies must explore new avenues for growth and staying competitive
  • Embracing a Third Way, MedTechs can invest in start-ups to access disruptive technologies, mitigate risks, foster growth, and competitive advantage
 
A Third Way Growth Strategy for MedTechs
 
MedTech industry leaders must welcome fresh ideas to maintain their competitive edge and ensure ongoing growth. However, the conventional avenues of development, such as merger and acquisitions (M&A) and in-house research and development (R&D), often encounter obstacles that diminish their effectiveness. As the industry advances, companies face the dual challenge of adopting new technologies while breaking down entrenched organisational barriers. In an era marked by transformative breakthroughs and turbulent market forces, adaptability and innovation are indispensable drivers of success.
 
The line separating established enterprises from agile newcomers has blurred, paving the way for potential collaboration and strategic investment. To excel in this environment, traditional MedTechs should consider recalibrating their conventional growth strategies. Rather than solely relying on M&A or low-risk tweaks to in-house R&D, they should explore a Third Way: investing in and collaborating with a range of innovative start-ups. Giant MedTech have been doing this for decades and reaping the benefits of nascent enterprises, fuelled by high-energy talent, leveraging novel technologies, and offering a fresh approach to growth and value creation.
 
Collaborating with early-stage entities empowers traditional firms to foster a culture of innovation and adaptability, thereby improving patient outcomes and strengthening healthcare systems to thrive in an era of unprecedented change. Effectively managing inventiveness becomes imperative for traditional MedTech companies to successfully navigate the evolving healthcare ecosystem.

 
In this Commentary

This Commentary emphasises the importance for MedTechs to define a clear strategic path in response to the challenges posed by rapid technological advancements, geopolitical shifts, and advancing market dynamics. We propose a Third Way that moves beyond conventional strategies of M&A and internal R&D. We advocate for investment in a varied portfolio of innovative early-stage enterprises focused on developing disruptive healthcare solutions and services. This approach aims to avoid the drawbacks associated with conventional growth strategies and set up MedTechs for long-term growth and improved competitiveness.
 
Challenges of M&A

For more than four decades, the MedTech industry has predominantly relied on M&A as its primary growth strategy, which, over time led to the financialisaton of the industry. Larger conglomerates emerged, but their size does not always translate into enhanced patient outcomes or improved operational efficiency. This pattern emphasises a tendency where short-term financial objectives frequently overshadow longer-term strategies focused on quality systems, organisational structure, and talent within the acquired companies.
In many instances, early-stage enterprises have deficiencies in their operational and human resource systems. These weaknesses are frequently overlooked or insufficiently addressed during the integration phase. While the repercussions of such oversight might not be readily apparent, they tend to surface over time, potentially hindering growth.
You might also like:

The Financialization Dilemma of MedTechs

 
The fallout from prioritising financial integration strategies can jeopardise the long-term viability of the merged entity and hamper its ability to innovate and adapt to shifting market dynamics. Successfully merging disparate corporate cultures, technological platforms, and operational processes requires meticulous planning and execution across all facets of the integration process. Neglecting to allocate adequate time and resources to address these non-financial aspects can lead to disruptions in workflow, employee discontent, and diminished performance.
 
Moving forward, corporations might consider adopting a more balanced approach to growth, one that not only factors in financial gains but also prioritises the assimilation of quality systems, organisational coherence, and human capital to ensure sustained success. Strategic complacency seems to be present in many large entities, and associated with an excessive dependence on conventional M&A for growth can dampen internal innovation.
 
Challenges of In-House R&D

Traditional MedTechs encounter challenges when considering disruptive in-house R&D endeavours. The inherent risks, coupled with resource constraints, often dissuade many traditional companies from pursuing innovative avenues of development. Also, complex regulatory environments present hurdles that require expertise, investment, and stringent compliance measures. The infrastructural needs for integrating new technologies exacerbate the situation, necessitating updates to current manufacturing facilities, supply chains, and distribution networks. These conditions emphasise the demanding nature of pursuing innovative R&D in-house. 

The demands of sales and marketing add additional complexity to internal development initiatives. New offerings require educating healthcare providers and consumers regarding their benefits, alongside developing specialised sales teams and tailored marketing strategies aligned with the product's unique demands. Incentivising sales teams to prioritise new offerings over established ones can be testing, which reinforces the hesitation of traditional MedTechs to pursue disruptive R&D projects.

 
A culture of risk aversion often prevails within traditional firms, leading to a reluctance to depart from established business models and technologies. This is reinforced by corporate structures that highlight stability and predictability over innovation and agility. Executives may hesitate to invest in ground-breaking R&D projects, opting instead for incremental improvements to existing devices. The allure of legacy products, despite their age and slow growth rates, provides a sense of security that dissuades corporations from exploring new technologies.
 
A Third Way

A Third Way for achieving growth and competitiveness, involves investing in innovative early-stage enterprises. Start-up culture thrives on creativity, fuelled by agility, entrepreneurial spirit, and a focus on disruptive solutions. Unlike traditional MedTechs, new ventures are free from the constraints of legacy systems, which enables them to take bold risks and explore new ideas. The collaborative culture of emerging businesses frequently attracts top talent from diverse disciplines, promoting interdisciplinary cooperation and fresh perspectives. This convergence of talent, flexibility, and risk-taking propels start-ups to the forefront of progress, extending the boundaries of what is achievable and contributing to transformative change in healthcare delivery and patient outcomes.
 
Engagement with entrepreneurial businesses warrants larger companies access to cutting-edge technologies while mitigating risk across a portfolio of ventures. Investment in early-stage entities opens avenues for collaboration, partnership, and potential acquisitions, enabling traditional firms to capitalise on emerging trends to maintain and enhance their competitiveness. Overall, embracing a broad-based investment strategy in start-ups represents a prudent approach for traditional MedTechs aiming to reconcile progress with risk.
You might also like:

Healthcare disrupters

Supporting a variety of new ventures that are developing novel products through off-balance sheet investments presents a strategic advantage for traditional corporations. This approach allows them to access advancements without immediately bearing the financial burden of traditional acquisitions, thereby preserving their financial flexibility, and safeguarding their core business. 
By providing tax benefits and mitigating the impact on financial ratios, these commitments contribute to the overall financial wellbeing of the company. Additionally, they facilitate low-risk incremental acquisitions. As start-ups mature and demonstrate success, traditional enterprises can acquire them, leveraging their initial investment and minimising the risk associated with unproven technologies. This model fosters an ecosystem where new entrepreneurial entities thrive with support from established players.
 
Investing in emerging businesses for MedTechs extends beyond financial contributions and can include injections of expertise and knowledge. Established firms possess the capability to offer invaluable guidance and mentorship, drawing on their experience in navigating complex regulations, executing successful clinical trials, and effectively scaling manufacturing operations. By sharing their expertise and knowhow, mature companies amplify the impact of their financial stakes and strengthen their ability and reputation to drive innovation. 

 
The Potential of Venture Arms for MedTechs

The creation of venture arms by leading MedTech companies has facilitated creativity and driven commercial success. Johnson & Johnson (J&J) and Medtronic, for example, have embraced this trend with positive outcomes. J&J's venture initiative, JLabs, was initiated in 2015 in San Francisco to nurture ~50 start-ups across a spectrum of healthcare sectors, including medical devices and digital health. Since then, it has burgeoned into a dynamic ecosystem with key incubation hubs worldwide, from New York to China.
 
While J&J typically refrains from immediate investments, its strategic commitments to enterprises like Mauna Kea Technologies, Protekt Therapeutics, Cara Care, Cala Health, and Sight Diagnostics demonstrate the company's interest in nurturing entrepreneurial solutions aligned with its strategic objectives. Similarly, Medtronic's venture arm has effectively made strategic investments in a diverse array of early-stage businesses, with Axonics as a notable example. Axonics' recent (January 2023) FDA approval for its fourth-generation rechargeable sacral neuromodulation system serves as a testament to the success that can arise from such collaborative endeavours.
 
Traditional MedTech companies can take valuable lessons from industry giants such as J&J and Medtronic, especially in establishing their own venture funds to invest in a range of start-ups. This strategic manoeuvre not only provides these companies access to cutting-edge technologies and disruptive innovations that might outstrip their internal development capacities but also allows them to diversify their product portfolio and helps mitigate risks associated with reliance on a narrow range of offerings.
 
Entrepreneurial ventures often boast agility, enabling them to swiftly bring products to market, surmount bureaucratic hurdles that larger corporations may face, cultivate a culture centred on innovation within their organisations, and inspire employees to explore fresh ideas and collaborate with external partners. 
However, this can only be achieved if the MedTech market offers realistic opportunities.
 
The MedTech Start-up Market

We have argued that the MedTech start-up market holds potential for traditional companies seeking to revitalise their portfolios to maintain and increase their competitiveness. However, what are the realities of this market? Recent studies shed light on its trends and opportunities, and from these, we can judge whether such investments strategies are a viable option for mature MedTechs.

A 2017 study by the Deloitte Center for Health Solutions and AdvaMed Accel suggested that venture capital investments in early-stage MedTechs were slowing because alongside lacklustre returns, investors showed reluctance towards unproven technologies, and were deterred by regulatory and reimbursement obstacles. However, findings of a similar study repeated in 2021 paint a more promising picture. Since 2017 and the onset of the Covid-19 pandemic in 2020, venture financing in early stage MedTechs surged by ~67%, suggesting a renewed investor confidence. Notably, the bulk of investments were towards late-stage diagnostic and digital companies, highlighting a shift in investor priorities towards more mature ventures. Furthermore, alternative financing avenues such as public markets and family offices have emerged as viable options, opening new pathways for entrepreneurial endeavours. Notwithstanding, amidst this surge, seed, and Series A funding continued to decline, which poses difficulties for fledgling MedTech entities.

For traditional MedTech companies contending with aging legacy products in slow-moving markets, bridging the funding gap presents an opportunity to enhance their growth prospects and strengthen their competitive position. As we have asserted, beyond financial backing, start-ups often seek guidance on regulatory navigation, clinical studies, intellectual property, and reimbursement procedures. Leveraging their wealth of experience and established networks, large firms are ideally situated to provide such valuable insights and support to emerging ventures. 

 
Takeaways

By strategically committing to a diverse range of start-ups, traditional firms bolster their capacity to navigate the complexities of the technology ecosystem. This proactive stance not only positions enterprises to shape the future of healthcare but also augments their prospects for sustained growth and competitiveness in an industry experiencing rapid evolution.
 
Collaborating with emerging businesses at the forefront of technological development empowers large corporations to respond adeptly to market dynamics and drive progress. Such strategic engagement reinforces their relevance in the market, fosters a culture of cooperation and improvement across the healthcare continuum, strengthens traditional enterprises' competitive edge and ensures their long-term viability.
 
The entrepreneurial spirit inherent in start-ups can rejuvenate the development pipelines of traditional MedTechs, enhancing their decision-making and cultivating an environment of creativity conducive to growth. Establishing a fund to invest in start-ups helps to reduce risk and maximise returns, thus protecting corporations against potential disruptions. Adaptation is crucial for survival, and the approach outlined in this Commentary provides traditional companies reliant on legacy offerings with an opportunity to adapt and thrive, reaffirming their relevance in an era characterised by constant change.
view in full page